ARVINAS
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.
ARVINAS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.arvinas.com
Total Employee:
251+
Status:
Active
Contact:
(203)535-1456
Email Addresses:
[email protected]
Total Funding:
461.6 M USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 Microsoft Akamai Hosted
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Arvinas
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Arvinas
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Arvinas
ArrowMark Partners
ArrowMark Partners investment in Post-IPO Equity - Arvinas
Citadel Global Equities
Citadel Global Equities investment in Post-IPO Equity - Arvinas
BB Biotech Ventures
BB Biotech Ventures investment in Post-IPO Equity - Arvinas
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Arvinas
RTW Investments
RTW Investments investment in Post-IPO Equity - Arvinas
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Arvinas
Avidity Partners
Avidity Partners investment in Post-IPO Equity - Arvinas
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-02-27 | Oerth Bio | Arvinas investment in Corporate Round - Oerth Bio | 55 M USD |
Key Employee Changes
Official Site Inspections
http://www.arvinas.com Semrush global rank: 1.86 M Semrush visits lastest month: 11.81 K
- Host name: ec2-34-201-227-227.compute-1.amazonaws.com
- IP address: 34.201.227.227
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Arvinas"
About - Arvinas
You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any …See details»
Arvinas - Crunchbase Company Profile & Funding
Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, …See details»
Investor Relations | Arvinas
Mar 4, 2025 Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, …See details»
Arvinas Company Profile | Management and Employees List
Arvinas Profile and History. Founded in 2013, Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life …See details»
Arvinas - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Arvinas . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 12. Number of Board …See details»
Arvinas - Funding, Financials, Valuation & Investors - Crunchbase
Arvinas is registered under the ticker NASDAQ:ARVN . Their stock opened with $16.00 in its Sep 26, 2018 IPO. Arvinas is funded by 21 investors. Great Point Partners and EcoR1 Capital are …See details»
Arvinas 2025 Company Profile: Stock Performance & Earnings
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, …See details»
Arvinas (ARVN) Company Profile & Description - Stock Analysis
Mar 25, 2025 Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The …See details»
Arvinas, Inc.
Arvinas, Inc. (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) D e l aw are 001-38672 47-2566120 (State or othe r jur i s di c ti on of i nc or por ati on) (Commi s s i on F i l e …See details»
Arvinas - VentureRadar
" Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, …See details»
Breaking Barriers in Biotech: The Arvinas Founding Story
In some ways, the idea behind Arvinas began with a failed venture capital (VC) pitch attempt. It was 20 years ago, and Arvinas founder, Craig Crews, was trying to start his first company. …See details»
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 ...
Mar 11, 2025 NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline …See details»
Arvinas Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Arvinas has 5 employees at their 1 location and $263.4 m in annual revenue in FY 2024. See insights on Arvinas including office locations, competitors, revenue, financials, …See details»
Arvinas Inc Company Profile - Arvinas Inc Overview - GlobalData
Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of neuroscience, …See details»
Arvinas, Inc. - Metastatic Breast Cancer Alliance
At Arvinas, we are committed to improving the lives of people living with serious disease, including breast cancer. Through our innovative PROTAC® (PROteolysis Targeting Chimera) protein …See details»
Leaps by Bayer
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening disease. Arvinas uses its proprietary technology …See details»
Benefits - Arvinas
Central to our organization is attracting, retaining, and engaging the best and brightest talent by sharing in the success of our organization: ... At Arvinas, our employees appreciate the …See details»
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 ...
Mar 11, 2025 NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase …See details»
Arvinas - Yale Biotech Club
Arvinas’ pipeline encompasses a range of validated and undruggable targets in oncology, immuno-oncology, and neuroscience. This includes three clinical-stage programs: ARV-110 …See details»
Arvinas Announces Oral Presentation at 2025 International …
Mar 27, 2025 Arvinas Inc. – Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV …See details»